Jupiter Topco LLC Purchases New Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Jupiter Topco LLC purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 36,543 shares of the biopharmaceutical company’s stock, valued at approximately $1,220,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. CANADA LIFE ASSURANCE Co grew its stake in Ultragenyx Pharmaceutical by 2.0% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after purchasing an additional 534 shares during the period. Van ECK Associates Corp raised its stake in shares of Ultragenyx Pharmaceutical by 26.1% during the 3rd quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 549 shares during the period. Tidal Investments LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 4.7% in the 2nd quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 564 shares during the last quarter. Rafferty Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 0.4% during the fourth quarter. Rafferty Asset Management LLC now owns 157,061 shares of the biopharmaceutical company’s stock valued at $3,612,000 after buying an additional 577 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 43.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 751 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
• Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
• Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
• Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
• Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure

Analysts Set New Price Targets

Several analysts have commented on RARE shares. Royal Bank Of Canada lowered shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research report on Thursday. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. The Goldman Sachs Group decreased their price target on shares of Ultragenyx Pharmaceutical from $28.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday. Evercore cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target on the stock. in a report on Thursday. Finally, Robert W. Baird downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $40.00 to $16.00 in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $36.63.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $15.30 on Friday. The stock has a market cap of $1.51 billion, a PE ratio of -2.62 and a beta of 0.31. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $13.81 and a fifty-two week high of $39.89. The stock has a fifty day moving average of $27.76 and a 200-day moving average of $24.97.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. During the same quarter in the prior year, the firm posted ($1.17) EPS. The firm’s quarterly revenue was up 28.5% on a year-over-year basis. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -3.98 EPS for the current year.

Insider Activity

In other news, EVP Karah Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Corsee Sanders sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the transaction, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 5.20% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.